팬젠

222110KOSDAQ의약품 제조업

54.0 / 100

Reference Date: 2026-04-13

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly up 4.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Panzen focuses on producing and selling biosimilar EPO drugs, offering CMO/CDO services, and developing biopharmaceuticals such as Factor VIII and Aflibercept. Its EPO product, approved in Malaysia, South Korea, the Philippines, Saudi Arabia, and Thailand, has expanded globally. The company's proprietary PanGen CHO-TECH™ technology enhances biopharmaceutical production efficiency through advanced cell line and process development.

Number of Employees

78people

Average Salary

57.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

33.56Industry Average 14.800.0Point

2.3x industry avg (risky)

PBR

2.30Industry Average 1.040.0Point

2.2x industry avg (risky)

ROE

7.48Industry Average 4.425.5Point

1.7x industry avg (good)

Debt Ratio

0.10Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.0% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲85.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 5,100Won52-week high 7,00052-week low 4,555

1-month return4.0Point

1m +4.29% (slight rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral사업보고서 (2025.12)2026-03-23
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-20
Neutral주식등의대량보유상황보고서(일반)2026-03-20